BackCytoMed Therapeutics Overview

CytoMed Therapeutics Current Cash

Track CytoMed Therapeutics's current cash ($2.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$2.10M
↓ 39.14% YoYΔ $-1.35M vs prior year quarter

Peer average

Loading

CytoMed Therapeutics Current Cash History

Loading

CytoMed Therapeutics vs. peers: Current Cash Comparison

Loading

CytoMed Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

CytoMed Therapeutics (GDTC) FAQ

The latest current cash for GDTC is $2.1M as of December 2025. That compares with $3.4M in the prior-year period — down 39.1% year over year. Investors often review this figure alongside CytoMed Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, GDTC's current cash moved from $3.4M to $2.1M — a 39.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CytoMed Therapeutics's operating scale or balance-sheet position.

A current cash figure of $2.1M for GDTC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GDTC's current cash ($2.1M), review year-over-year change from $3.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.